Pharmaceutical Business review

Large scale trial confirms efficacy of Shire’s Adderall XR

Nearly 75% of study participants experienced improvement in ADHD symptoms, according to preliminary results of the study dubbed the Quality of Life, Effectiveness, Safety, and Tolerability trial (QUEST).

In the study results for the intent-to-treat population (702 patients) indicated that ADHD rating scale total scores were significantly improved by approximately 60 percent at the end of the core 10-week phase.

The results were presented at the annual meeting of Children and Adults with attention-deficit/hyperactivity disorder (CHADD).

“Quest is the largest study of its kind to date to document improvements in symptoms of adult ADHD,” said QUEST investigator Dr David Goodman, director at the Adult Attention Deficit Disorder Center of Maryland. “The good news for adults with ADHD is that Adderall XR was shown to improve ADHD symptoms and was also generally well tolerated.”